Severe PAT miss masks guarded recovery narrative

Reported revenue +3.0% YoY; ex-Pril/FA basis unclear from filed results

950 bps compression confirmed by extreme margin pressure in delivered result

8.4% OPM matches delivered result exactly

Despite pricing, NPM fell 50.8% YoY; suggests input cost inflation ~15-16% far exceeded pricing realization

Q1 reported +3% YoY; heavy dependency on H2 recovery and exclusions

Prior guidance warned of 'continued margin pressure'; Q1 delivered -820 bps EBITDA hit, well exceeding caution. NPM fell 50.8% YoY vs. any reasonable prior expectation.

4-4.5% price increase flagged in prior calls; only 3% flowed in Q1, 1-1.5% pushed to Q2. Competitive action (Dishwash explicitly called out as 'competitive') limiting pass-through.

Reaffirmed 'H2 substantially better than H1,' but now explicitly linked to crude stabilization from October onwards. Downside risk if geopolitics persist or demand slips.

Reconfirmed ex-Pril/FA, but Q1 +3% reported growth creates gap. Full-year achievement requires aggressive H2 acceleration; mid-year update risk.

Management vaguely promised 'good news' on Personal Care, beauty/cosmetics, and non-crude-linked products; zero specifics or timelines shared. 1.5 years of R&D work ongoing but no launches announced.

Competitive action and SKU-level price reductions. Blended 4-4.5% total; Personal Care 9-10%, Fabric Care ~5%, Dishwash 'competitive.' Mix varies by category and competitive intensity.

Goal is to swing back to historical levels. Large portion linked to crude, but cost optimization and pricing actions already in place. Cannot ignore market reality; crude behavior is 'anybody's guess.'

Launched 3-4 months ago. Early-stage scale-up; making 'reasonably' good progress per expectations. More detail by year-end.

Premiumization works in Personal Care and high-involvement categories. In home care, premium brands are discounted; market still price-driven. Exo operates at top end of price ladder; Henko premium franchise ongoing.

General trade on advanced payment basis; distributor stock at 15-20 days; hygiene maintained across all channels. Disciplined discipline; no one-to-one link with balance sheet strength.

Royalty amount is small; no one-to-one mapping to line items. Cost-saving initiatives and innovation investment are happening in parallel.

Henkel decided not to renew; no manufacturing/distribution beyond 31-Apr. No specific cooling-off clause. Matter is before the court; cannot comment beyond this.

Priced at par with competition. Trusted molecule, stable, lab-tested superior product. Government-approved. Acts in 2 minutes. Second organized player; strong winning product.

Looked at TTK; 2 of 4 divisions not aligned, 2 had overlap. Rejected. Looking at assets aggressively but with stringent filters; must align with growth strategy. No acquisitions just for the sake of size.

Endeavor to deliver from current quarter. 3-4% price increases; high single-digit volume growth expected through FY27. FY27 excluding Pril/FA, double-digit growth target.

Doing reasonably okay; on positive side ex-Pril/FA. Urban demand pressure exists but general trade holding up. E-commerce/quick commerce strongest channels, 25-30% growth range.

Continues to deliver good growth. Strong product portfolio across formats/channels. Do not see material reason for slowdown unless external events. Growth momentum will continue.

Will see at that point in time. Right now, we'll see what we have to do. More people welcome to the party.

Sharp Q1 margin contraction related to raw material inflation; pricing still catching up. Crude volatility high. Recent trends 'relatively encouraging.' Not materially lower than Q1, but progressive improvement ahead.

Not a commodity business. Input inflation 30-35% (unprecedented); 90% business crude-linked. Took 3% pricing + 3-4% efficiencies to contain at 9.5% impact. Diversification and innovation give confidence in margin recovery if external environment stabilizes.

Pricing is competitive. Most products at par with competition. When Jyothy launches, competition reduces prices. Consumer demand elasticity matters. 90% home care has direct crude relation; other players have diversified portfolios. On journey to increase Personal Care and high-margin products.

Trusted stable molecule; lab results show superiority vs. competitors. Government-approved. Acts in 2 minutes. Communication will happen as product scales; too early to tell right now.

Management restated aspiration; Q1 +3% reported vs +8.1% ex-Pril creates mid-year execution risk. Dependent on H2 acceleration; no absolute FY27 number disclosed.

Q1 at 8.4%; Q2 expected softer (high-cost inventory flow-through). Recovery from October onwards contingent on crude price stability; 'progressive' recovery, not sharp rebound.

Long-term aspiration; heavily dependent on crude deflation and/or successful diversification into high-margin Personal Care/new products. Timeline unclear; no interim FY27/FY28 target.

90% business home care (crude-linked). When Jyothy launches, competition cuts prices immediately. Pricing power appears limited to match competitive moves, not exceed cost inflation. Analyst Logeshkumar questioned if this is 'commodity business behavior'; Jyothy deflected but acknowledged 90% home care tie to crude.

90% of business and 30-35% of Q1 costs driven by crude spike (60-65% → 100+). Management explicitly acknowledges 'heavy dependence on crude-linked material is a risk.' No hedging strategy disclosed. Margin recovery entirely hinges on crude stabilization; if geopolitical risk persists, so will margin compression.

Management guided H2 'substantially better than H1,' but recovery is 'gradual' and tied to multiple contingencies: crude stabilization (Oct onwards), demand recovery, inventory flow-through, and effectiveness of pricing actions. Q2 expected to be soft (high-cost inventory impact). No interim recovery visible before Oct; CFO said margin not 'materially lower' than Q1 but not improving either.

Pril exited 31-May 2026 (end of licensing agreement with Henkel); matter before court. Exo liquid launched to fill gap but is early-stage. Ronak Shah asked about 'larger player introducing dishwash product'; management deflected, saying 'will see at that point in time.' Risk of new entrant and/or Henkel Pril return (if court ruling favorable to Henkel) could dent Exo uptake.

Personal Care segment reported as 'subdued' in Q1 due to aggressive 9-10% price increases and supply chain disruptions. Management confident of 'recovery trajectory' but provides no specific timeline or volume/value recovery thresholds. Soap noodle prices rising from June onwards; management 'monitoring' whether this is temporary or sustained inflationary cycle.

Urban markets remained subdued Q1 after recovery signs in H2 FY26. 'Higher household expenses, continued pressure on discretionary spends, and cautious consumer sentiment affected urban consumption.' GT (general trade) growth muted due to lower urban demand; other channels delivered 'impressive growth.' Risk: if urban recovery delays, overall volume momentum slows despite channel strength.